Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny eye implant could free glaucoma patients from daily drops

NCT ID NCT05024695

Disease control Sponsor: iSTAR Medical Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This trial tests a small implant called MINIject that is placed inside the eye to help drain fluid and lower pressure in people with open-angle glaucoma. About 975 adults who have already had cataract surgery are taking part. The goal is to see if the implant safely reduces eye pressure enough to reduce or replace the need for daily eye drops.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MINIject implant (a tiny drainage device placed in the eye)
What this could lead to
If it works, this implant could help people with glaucoma control their eye pressure with fewer or no daily eye drops.
What could go wrong
This is a large but still early-stage study. The implant may not lower pressure enough for everyone, and risks include infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 975 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2021

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

46 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Males and females, 46 years of age or older * A diagnosis of primary open-angle glaucoma, who are candidates for medical therapy, laser treatment, or glaucoma-filtering surgery * Pseudophakic with prior uncomplicated cataract surgery Key Exclusion Criteria: * Angle closure, congenital, or secondary glaucoma * Diagnosed degenerative visual disorders * Clinically significant intraocular inflammation or infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Choroidal Effusions glaucoma open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma

Contacts and locations

Locations

  • Apex Eye Clinical Research, LLC

    Mason, Ohio, 45040, United States

  • Arizona Advanced Eye Research Institute

    Glendale, Arizona, 85306, United States

  • Berkeley Eye Center

    Houston, Texas, 77027, United States

  • Beverly Hills Institute of Ophthalmology

    Beverly Hills, California, 90210, United States

  • Center for Sight Las Vegas

    Las Vegas, Nevada, 89145, United States

  • Clinique Opthalmologies Bellevue

    Montreal, Canada

  • El Paso Eye Surgeons

    El Paso, Texas, 79922, United States

  • Eye Associates of Fort Myers

    Fort Myers, Florida, 33901, United States

  • Eye Centers of Racine and Kenosha

    Kenosha, Wisconsin, 53142, United States

  • Eye Consultants PC

    Omaha, Nebraska, 68124, United States

  • Glaucoma Associates of Texas

    Dallas, Texas, 75231, United States

  • Glaucoma Service Moorfields Eye Hospital

    London, United Kingdom

  • Grand Junction Eye Care

    Grand Junction, Colorado, 81501, United States

  • Houston Eye Associates

    Houston, Texas, 77025, United States

  • Illinois Eye Center

    Peoria, Illinois, 61615, United States

  • Imperial College Healthcare NHS Trust Western Eye Hospital

    London, United Kingdom

  • Intermountain Eye Center

    Eagle, Idaho, 83616, United States

  • KCL Frost Eye Research Department St Thomas' Hospital

    London, United Kingdom

  • LA Eye and Laser

    Alexandria, Louisiana, 71303, United States

  • Minnesota Eye Consultants

    Bloomington, Minnesota, 55431, United States

  • NYU Langone Ophthalmology

    New York, New York, 10017, United States

  • Oklahoma Eye Surgeons

    Oklahoma City, Oklahoma, 73112, United States

  • Ophthalmology Associates

    Fort Worth, Texas, 76102, United States

  • Prism Eye Institute

    Oakville, Ontario, L6H 0J8, Canada

  • Queen Victoria Hospital NHS Foundation Trust

    East Grinstead, United Kingdom

  • R and R Eye Research

    San Antonio, Texas, 78229, United States

  • Reeve Woods Eye Center

    Chico, California, 95926, United States

  • Research & Development Unit, Learning and Research Centre (LaRC), York Hospital

    York, United Kingdom

  • Sacramento Eye Consultants, A Medical Corporation

    Sacramento, California, 95815, United States

  • Spokane Eye Clinical Research

    Spokane, Washington, 99204, United States

  • Stiles Eyecare Excellene and Glaucoma Institute

    Overland Park, Kansas, 66213, United States

  • Swiss Glaucoma Research Foundation Swiss Visio Montchoisi

    Lausanne, Switzerland

  • The Eye Institute of Utah

    Salt Lake City, Utah, 84107, United States

  • The Institute de l'Oeil des Laurentides

    Boisbriand, Quebec, J7N0C2, Canada

  • Vanderbilt Eye Institute

    Nashville, Tennessee, 37232, United States

  • Virdi Eye Clinic

    Rock Island, Illinois, 61201, United States

  • Vold Vision

    Fayetteville, Arkansas, 72704, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.